Nicollet Mall

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Retrieved on: 
Friday, April 12, 2024
Sale, Prospectus, Capital market, RBC Capital Markets, Broadridge Financial Solutions, Montgomery Street, RBC, Suite, Security (finance), Research, Nicollet Mall, Form, Attention, Therapy, Telephone, SAN, Needham & Company

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share.

Key Points: 
  • SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share.
  • The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $175.0 million.
  • Nurix has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares of common stock in connection with the public offering.
  • The offering is expected to close on or about April 16, 2024, subject to the satisfaction of customary closing conditions.

Nurix Therapeutics Announces Proposed Public Offering

Retrieved on: 
Thursday, April 11, 2024
Sale, Prospectus, Cancer, RBC Capital Markets, Broadridge Financial Solutions, Montgomery Street, Suite, Security (finance), Research, Nicollet Mall, Form, Patient, Inflammation, Attention, Therapy, Telephone, SAN, Needham & Company

In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions.

Key Points: 
  • In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the proposed offering.
  • Needham & Company, LLC and RBC Capital Markets, LLC are acting as lead managers for the proposed offering.

Fulton Financial Announces Closing of $287.5 Million Offering of Common Stock

Retrieved on: 
Wednesday, May 1, 2024
Banking, Professional Services, Finance, Bank of America, Sale, Prospectus, Fulton Financial Corporation, Corporation, Republic Bank, Federal Deposit Insurance Corporation, FULT, Communication, Nicollet Mall, Form, Exercise, EDGAR, Acquisition, BofA Securities, Attention, Telephone, Security (finance)

Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced the closing of its public offering of 19,166,667 shares of its common stock (the “common stock”), at a price to the public of $15 per share, which included 2,500,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.

Key Points: 
  • Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced the closing of its public offering of 19,166,667 shares of its common stock (the “common stock”), at a price to the public of $15 per share, which included 2,500,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
  • Piper Sandler and BofA Securities acted as joint book-running managers for the offering.
  • The Corporation received net proceeds from the offering of approximately $273.5 million, after deducting underwriting discounts and before deducting transaction expenses.
  • The shares of common stock to which this communication relates were issued pursuant to an effective registration statement on Form S-3 (File No.

Fulton Financial Announces Launch of Common Stock Offering

Retrieved on: 
Monday, April 29, 2024
Banking, Professional Services, Bank of America, Sale, Prospectus, Fulton Financial Corporation, Corporation, Republic Bank, Federal Deposit Insurance Corporation, FULT, Communication, Nicollet Mall, Form, EDGAR, Acquisition, BofA Securities, Attention, Telephone, Security (finance)

Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced that it commenced an underwritten public offering of shares of its common stock.

Key Points: 
  • Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced that it commenced an underwritten public offering of shares of its common stock.
  • The Corporation expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.
  • Piper Sandler and BofA Securities are acting as joint book-running managers for the offering.
  • The offering is being made only by means of a prospectus supplement and accompanying base prospectus.

Fulton Financial Announces Pricing of $250 Million Offering of Common Stock

Retrieved on: 
Monday, April 29, 2024
Banking, Professional Services, Finance, Bank of America, Sale, Prospectus, Fulton Financial Corporation, Corporation, Republic Bank, Federal Deposit Insurance Corporation, FULT, Communication, Nicollet Mall, Form, EDGAR, Acquisition, BofA Securities, Attention, Telephone, Security (finance)

Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced the pricing of its public offering of 16,666,667 shares of its common stock (the “common stock”), at a price to the public of $15 per share, for an aggregate offering amount of $250 million.

Key Points: 
  • Fulton Financial Corporation (NASDAQ: FULT) (the “Corporation”) today announced the pricing of its public offering of 16,666,667 shares of its common stock (the “common stock”), at a price to the public of $15 per share, for an aggregate offering amount of $250 million.
  • In addition, the Corporation has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of common stock at the public offering price, less underwriting discounts.
  • Piper Sandler and BofA Securities acted as joint book-running managers for the offering.
  • The offering is being made only by means of a prospectus supplement and accompanying base prospectus.

UMB Financial Corporation Announces Pricing of an Underwritten Offering of 2,800,000 Shares of Common Stock

Retrieved on: 
Monday, April 29, 2024
Banking, Professional Services, Finance, Bank of America, UMBF, Sale, Prospectus, RBC Capital Markets, UMB Financial Corporation, Vesey Street, Security (finance), Nicollet Mall, Form, Exercise, Varick Street, Morgan Stanley, 2nd Floor, Wellington Management Company, BofA Securities, S-3, UMB, Attention, Telephone

The underwriters have been granted the option to purchase up to an additional 420,000 shares of UMB’s common stock.

Key Points: 
  • The underwriters have been granted the option to purchase up to an additional 420,000 shares of UMB’s common stock.
  • Such borrowed shares of UMB’s common stock will be delivered by BofA Securities (in such capacity, the “forward seller”) for sale to the underwriters in the offering.
  • UMB will not receive any proceeds from the sale of the shares of its common stock sold by the forward seller to the underwriters.
  • The offering of these securities may be made only by means of a prospectus supplement and accompanying base prospectus relating to this offering.

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Retrieved on: 
Thursday, March 28, 2024
Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.
  • All shares and pre-funded warrants in the offering are being offered by Praxis.
  • In addition, Praxis has granted the underwriters a 30-day option to purchase up to 530,973 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about April 2, 2024, subject to market conditions and the satisfaction of customary closing conditions.

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Retrieved on: 
Wednesday, March 27, 2024
Floor, Needham & Company, Madison Avenue, Central nervous system, Form, Telephone, CNS, Truist, Sale, Attention, Security (finance), Guggenheim Partners, Form S-3, Praxis, Nicollet Mall

All securities in the offering will be offered by Praxis.

Key Points: 
  • All securities in the offering will be offered by Praxis.
  • Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering.
  • The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed.
  • The proposed offering will be made only by means of a preliminary prospectus supplement and the accompanying base prospectus.

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

Retrieved on: 
Monday, March 25, 2024
SVB Securities, Telephone, Oppenheimer Holdings, Sale, Attention, Prospectus, Therapy, Nicollet Mall, State Street

WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.

Key Points: 
  • WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.
  • At closing, the aggregate gross proceeds of the offering to Aquestive, before deducting underwriting discounts and commissions and other offering expenses paid by Aquestive, were approximately $75.0 million.
  • Leerink Partners and Piper Sandler acted as joint bookrunning managers for the offering.
  • H.C. Wainwright & Co. and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as financial advisors to the Company.

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

Retrieved on: 
Wednesday, March 20, 2024
SVB Securities, Epilepsy, Anaphylaxis, Telephone, Patient, Adrenaline, Ageing, Oppenheimer Holdings, Sale, Public expenditure, Attention, Prospectus, Therapy, Nicollet Mall, State Street

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.

Key Points: 
  • WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share.
  • The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million.
  • In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions.